Duloxetine

Summary

Duloxetine (CHEMBL1175) is an approved small molecule (ATC N06AX21) targeting HTR6, ZC3H14, and HTR2A; indicated across 37 conditions including osteoarthritis, knee and anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX21
• Targets: 6 (HTR6, ZC3H14, HTR2A…)
• Indications: 37 conditions
• Clinical trials: 331
• Chemistry: 297.4 Da · C18H19NOS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1175
Name	Duloxetine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60835
ChEBI	CHEBI:36795
ATC	N06AX21
Molecular formula	C18H19NOS
Molecular weight	297.4
InChIKey	ZEUITGRIYCTCEM-KRWDZBQOSA-N

SMILES: CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32

IUPAC name: (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine

Also known as: Duloxetina, Duloxetine, LY-248686, LY248686, (S)-Duloxetine, duloxetine, S-Duloxetine, SID26719725, SID26757978, SID49681583, SID124893161, DULOXETINE

Parent form; salt/anhydrous children: CHEMBL1200328

Patent coverage: 7,911 distinct patent families (28,527 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 28,258 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR6	5-HT6 receptor	Antagonist	6.4	0.2%	P50406
ZC3H14	zinc finger CCCH-type containing 14	Binding		0%	Q6PJT7
HTR2A	5-HT2A receptor	Antagonist	6.3	0%	P28223
HTR2C	5-HT2C receptor	Antagonist	6	0%	P28335
SLC6A2	NET	Inhibition	8.22	0.4%	P23975
SLC6A4	SERT	Inhibition	8.3	0.7%	P31645

Broader ChEMBL bioactivity targets: 43 (assay-derived). Sample: Histone-lysine N-methyltransferase 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Alpha-2B adrenergic receptor, A-type voltage-gated potassium channel KCND3, Sodium channel protein type 5 subunit alpha, Voltage-gated L-type calcium channel, P2X purinoceptor 4.

Bioactivity

ChEMBL activities: 107 potent at pChembl ≥ 5 of 127 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P31652	10.09	Ki	0.08	nM	CHEMBL_ACT_13325640
SLC6A4	9.62	Ki	0.24	nM	CHEMBL_ACT_13325672
SLC6A4	9.5	IC50	0.32	nM	CHEMBL_ACT_12668699
SLC6A4	9.3	Ki	0.5	nM	CHEMBL_ACT_2714826
SLC6A4	9.1	Ki	0.8	nM	CHEMBL_ACT_652283
SLC6A4	9.1	Ki	0.79	nM	CHEMBL_ACT_662615
SLC6A4	8.85	Ki	1.4	nM	CHEMBL_ACT_655872
SLC6A2	8.8	IC50	1.58	nM	CHEMBL_ACT_12668749
SLC6A4	8.64	IC50	2.3	nM	CHEMBL_ACT_13325591
SLC6A4	8.52	IC50	3	nM	CHEMBL_ACT_2483387
SLC6A4	8.52	AC50	3	nM	CHEMBL_ACT_25149883
SLC6A4	8.52	IC50	3	nM	CHEMBL_ACT_2522762
SLC6A4	8.52	IC50	3	nM	CHEMBL_ACT_3285117
SLC6A2	8.4	IC50	4	nM	CHEMBL_ACT_2483369
SLC6A2	8.4	IC50	4	nM	CHEMBL_ACT_2522735
SLC6A4	8.4	IC50	4	nM	CHEMBL_ACT_2674398
SLC6A2	8.4	IC50	4	nM	CHEMBL_ACT_3285116
SLC6A4	8.34	Ki	4.6	nM	CHEMBL_ACT_1617662
P31652	8.34	Ki	4.6	nM	CHEMBL_ACT_2265484
SLC6A2	8.34	Ki	4.6	nM	CHEMBL_ACT_24987129
SLC6A4	8.3	Ki	5	nM	CHEMBL_ACT_2163924
SLC6A2	8.3	IC50	5	nM	CHEMBL_ACT_2674440
SLC6A4	8.3	Ki	5	nM	CHEMBL_ACT_3226179
SLC6A4	8.3	Ki	5	nM	CHEMBL_ACT_3309571
SLC6A2	8.22	Ki	5.97	nM	CHEMBL_ACT_12169776
SLC6A4	8.22	IC50	6	nM	CHEMBL_ACT_1753742
SLC6A4	8.22	IC50	6	nM	CHEMBL_ACT_1755301
SLC6A4	8.22	IC50	6	nM	CHEMBL_ACT_2020842
SLC6A4	8.18	IC50	6.6	nM	CHEMBL_ACT_2100220
SLC6A4	8.18	IC50	6.6	nM	CHEMBL_ACT_2397254

Target pathways

Aggregated over 6 target gene(s): HTR6, ZC3H14, HTR2A, HTR2C, SLC6A2, SLC6A4.

Top Reactome pathways

21 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	3	HTR2A, HTR2C, HTR6
Signaling by GPCR	3	HTR2A, HTR2C, HTR6
Class A/1 (Rhodopsin-like receptors)	3	HTR2A, HTR2C, HTR6
Amine ligand-binding receptors	3	HTR2A, HTR2C, HTR6
GPCR downstream signalling	3	HTR2A, HTR2C, HTR6
Serotonin receptors	3	HTR2A, HTR2C, HTR6
GPCR ligand binding	3	HTR2A, HTR2C, HTR6
G alpha (q) signalling events	2	HTR2A, HTR2C
SLC-mediated transport of neurotransmitters	2	SLC6A2, SLC6A4
Neurotransmitter clearance	1	SLC6A4
Transmission across Chemical Synapses	1	SLC6A4
Neuronal System	1	SLC6A4
Disease	1	SLC6A2
Serotonin clearance from the synaptic cleft	1	SLC6A4
Transport of small molecules	1	SLC6A2
G alpha (s) signalling events	1	HTR6
R-HSA-425366	1	SLC6A2
SLC-mediated transmembrane transport	1	SLC6A2
SLC transporter disorders	1	SLC6A2
Defective SLC6A2 causes orthostatic intolerance (OI)	1	SLC6A2
Disorders of transmembrane transporters	1	SLC6A2

Dominant GO biological processes

GO term	Targets
chemical synaptic transmission	4
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	3
signal transduction	3
G protein-coupled receptor signaling pathway	3
G protein-coupled serotonin receptor signaling pathway	3
response to xenobiotic stimulus	3
intracellular calcium ion homeostasis	2
phospholipase C-activating serotonin receptor signaling pathway	2
serotonin receptor signaling pathway	2
memory	2
positive regulation of phosphatidylinositol biosynthetic process	2
positive regulation of fat cell differentiation	2
behavioral response to cocaine	2
release of sequestered calcium ion into cytosol	2
positive regulation of ERK1 and ERK2 cascade	2

Indications & clinical

Indications

37 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616
anxiety	3	MONDO:0011918	EFO:0005230
fibromyalgia	3	MONDO:0005546	EFO:0005687
biliary dyskinesia	3	MONDO:0005667	EFO:0007169
diabetic neuropathy	3	MONDO:0006626	EFO:1000783
dementia	3	MONDO:0001627	HP:0000726
peripheral neuropathy	3	MONDO:0005244	EFO:0003100
major depressive disorder	3	MONDO:0002009	MONDO:0002009
depressive disorder	3	MONDO:0002050	MONDO:0002050
generalized anxiety disorder	3	MONDO:0001942	EFO:1001892
osteoarthritis	3	MONDO:0005178	MONDO:0005178
Parkinson disease	3	MONDO:0005180	MONDO:0005180
burning mouth syndrome	3	MONDO:0006687	EFO:1000850
diabetes mellitus	2	MONDO:0005015	EFO:0000400
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
myalgic encephalomeyelitis/chronic fatigue syndrome	2	MONDO:0005404	EFO:0004540
neuralgia	2	MONDO:0021667	EFO:0005762
diabetic kidney disease	2	MONDO:0005016	EFO:0000401
interstitial lung disease	2	MONDO:0015925	EFO:0004244
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
alcohol abuse	2	MONDO:0002046	MONDO:0007079
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
methamphetamine dependence	1	MONDO:0005419	EFO:0004701
stroke disorder	0	MONDO:0005098	EFO:0000712
post-traumatic stress disorder	0	MONDO:0005146	EFO:0001358

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 331.

Phase distribution

Phase	Trials
PHASE4	99
PHASE3	96
Not specified	66
PHASE2	42
PHASE1	14
PHASE2/PHASE3	7
EARLY_PHASE1	4
PHASE1/PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04245436	PHASE4	RECRUITING	Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
NCT04245748	PHASE4	RECRUITING	Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
NCT05851898	PHASE4	RECRUITING	Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
NCT05851976	PHASE4	RECRUITING	Duloxetine for LBP
NCT05976347	PHASE4	RECRUITING	Identifying and Treating Depression in the Orthopaedic Trauma Population
NCT06232473	PHASE4	RECRUITING	Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder
NCT06245109	PHASE4	RECRUITING	Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
NCT06423716	PHASE4	RECRUITING	Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)
NCT06807866	PHASE4	RECRUITING	Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT
NCT06968624	PHASE4	NOT_YET_RECRUITING	Ketamine for Postherpetic Neuralgia With Depression
NCT00067912	PHASE4	COMPLETED	Duloxetine vs. Active Comparator for the Treatment of Depression
NCT00071695	PHASE4	COMPLETED	Duloxetine vs. Active Comparator in the Treatment of Patients With Depression
NCT00177671	PHASE4	COMPLETED	Antidepressant Medication Plus Donepezil for Treating Late-life Depression
NCT00191061	PHASE4	COMPLETED	A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder
NCT00191932	PHASE4	COMPLETED	Switching to Duloxetine From Other Antidepressants
NCT00224302	PHASE4	COMPLETED	Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
NCT00244296	PHASE4	COMPLETED	To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
NCT00266643	PHASE4	COMPLETED	Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain
NCT00296699	PHASE4	COMPLETED	A Pilot Study Assessing Duloxetine’s Efficacy in Atypical Depression
NCT00322621	PHASE4	COMPLETED	Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT00360724	PHASE4	COMPLETED	Duloxetine for Chronic Depression: a Double-blind Study
NCT00385671	PHASE4	COMPLETED	An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
NCT00398632	PHASE4	TERMINATED	Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
NCT00401258	PHASE4	COMPLETED	An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
NCT00406848	PHASE4	COMPLETED	A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
NCT00422162	PHASE4	COMPLETED	A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
NCT00437125	PHASE4	COMPLETED	Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson’s Disease
NCT00438971	PHASE4	COMPLETED	The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
NCT00443352	PHASE4	COMPLETED	A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache
NCT00464698	PHASE4	COMPLETED	Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
NCT00479726	PHASE4	COMPLETED	Lilly’s Emotional and Physical Symptoms of Depression Study (LEAPS)
NCT00494377	PHASE4	COMPLETED	Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
NCT00517985	PHASE4	COMPLETED	Duloxetine for Perimenopausal Depression
NCT00531895	PHASE4	COMPLETED	An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache
NCT00532480	PHASE4	COMPLETED	Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
NCT00536471	PHASE4	COMPLETED	A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
NCT00607789	PHASE4	COMPLETED	Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression
NCT00609557	PHASE4	COMPLETED	A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain
NCT00619983	PHASE4	TERMINATED	Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
NCT00666757	PHASE4	COMPLETED	A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (4) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for duloxetine and CYP2D6	DPWG	CYP2D6
Annotation of CPIC Guideline for duloxetine and CYP2D6	CPIC	CYP2D6
Annotation of CPIC Guideline for desvenlafaxine, duloxetine, fluoxetin	CPIC	HTR2A
Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetin	CPIC	SLC6A4

PharmGKB also curates 73 clinical and 101 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

777 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
AMIODARONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ASENAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
BENZTROPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CARVEDILOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CLEMASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CLOZAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
DESLORATADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
DOXEPIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
EBASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ECONAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
FLUOXETINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
HALOPERIDOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
HALOPROGIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ILOPERIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
IMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
LOXAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
MEPAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
METHAPYRILENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
MIANSERIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
MICONAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
NEFAZODONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ORPHENADRINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PIMOZIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PIPAMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PROMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PROMETHAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PROPAFENONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PROPRANOLOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
RALOXIFENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
RISPERIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
SERTINDOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
SUNITINIB	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
TAMOXIFEN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
TEGASEROD	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
TERFENADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
THIORIDAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ENCLOMIPHENE	ChEMBL	Phase 3	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
ZUCLOPENTHIXOL	ChEMBL	Phase 3	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
METERGOLINE	ChEMBL	Phase 2	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
PENFLURIDOL	ChEMBL	Phase 2	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4
RITANSERIN	ChEMBL	Phase 2	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A4